GALVANIZE
10.3.2020 14:02:15 CET | Business Wire | Press release
Galvanize , the leader in SaaS governance, risk, and compliance (GRC) software, is pleased to announce that it has been named a Leader in The Forrester Wave™: Governance, Risk, and Compliance Software, Q1 2020.
Galvanize received the top scores possible in the risk and control management, document management, audit management, and IT risk management criteria. In addition, the company was among the top ranked in the criteria of advanced predictive analytics, which is defined as “superior capabilities relative to others in the evaluation, including AI and ML capability to support advanced modelling in Python and R, advanced anomaly detection, and continuous auditing.”
“We’re extremely proud to be named as a Leader in Forrester’s rigorous evaluation system,” said Dan Zitting, chief product & strategy officer, Galvanize. “We believe this accomplishment is a testament to the hard work of marrying our GRC platforms to create an end-to-end system that sets the industry standard for stronger IT security, risk management, compliance, and assurance.”
The report notes the company’s successful integration of ACL and Rsam to create a combined industry catalyst. According to the report, the HighBond platform, which has achieved FedRAMP Moderate authorization, “combines Rsam’s aptitude for collecting and operationalizing data with ACL’s powerful analytics and robotic process automation, enabling GRC pros to capitalize on digital transformation”. The report explains: “Notwithstanding the sophistication, customers enjoy managing the platform themselves and appreciate Client Partners, the vendor’s unique take on customer success that combines guidance, best practices, and access to other customers to help solve similar problems.”
“We’re witnessing a shift among the world’s most influential businesses, as they demand value from organizations that stretch beyond financial profit,” said Laurie Schultz, president & CEO, Galvanize. “Being recognized as a Leader by Forrester is extremely impactful, as it corroborates our unique vision to create a comprehensive GRC offering worthy of tomorrow’s workforce, as well as bringing us closer to our goal of consolidating the GRC industry, and being the operating system for conscious organizations.”
The Forrester Wave™ is one of the industry’s most complete and detailed analyses, using a transparent methodology composed of vendor surveys, product demos, and customer reference calls to compare top players in the market. This latest recognition builds on a long history of industry recognition among leading analyst firms for Galvanize. The company was named a Leader in Gartner Magic Quadrant for IT Vendor Risk Management Tools in December 2019 and a Leader in Gartner Magic Quadrant for IT Risk Management in July 2019.
A full, complimentary version of the report, The Forrester Wave™: Governance, Risk, and Compliance Software, Q1 2020 is available for download from Galvanize at: https://info.wegalvanize.com/forrester-wave-grc-platforms-2020-report.html
To learn more about Galvanize and its comprehensive GRC platform, visit: wegalvanize.com .
About Galvanize:
Galvanize builds award-winning, cloud-based security, risk management, compliance, and audit software to drive change in some of the world’s largest organizations. We’re on a mission to unite and strengthen individuals and entire organizations through the integrated HighBond software platform. With more than 6,300 customer organizations in 130 countries, Galvanize is connecting teams in many of the Fortune 1,000 and S&P 500 companies, and hundreds of government organizations, banks, manufacturers, and healthcare organizations. Whether these professionals are managing threats, assessing risk, measuring controls, monitoring compliance, or expanding assurance coverage, HighBond automates manual tasks, blends organization-wide data, and broadcasts it in easy-to-share dashboards and reports. But we don’t just make technology—we provide tools that inspire individuals to achieve great things and do heroic work in the process.
Supporting Resources:
Website: www.wegalvanize.com
Twitter: https://twitter.com/wegalvanize
LinkedIn: https://linkedin.com/company/wegalvanize
©2020 ACL Services Ltd. ACL, Galvanize, the Galvanize logo, HighBond, and the HighBond logo are trademarks or registered trademarks of ACL Services Ltd. dba Galvanize. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200310005234/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom